Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data

Impact · against what's priced in

The clinical data for atebimetinib + mGnP in pancreatic cancer represents a significant positive catalyst due to a 64% 12-month overall survival rate compared to the 35% standard of care. Regulatory alignment for a Phase 3 trial by mid-2026 further reduces the risk profile for the company's lead candidate.

IMRX+0.90

No priced-in read yet

In context

The combination therapy's 64% 12-month overall survival rate nearly doubles the 35% standard-of-care rate, providing strong clinical evidence of efficacy in 1st-line pancreatic cancer.

Read from the article alone

• biotech
• IMRX
• clinical trials
• drug pipeline
• health care
• oncology
• pancreatic cancer
• phase 3

Search tags